SEP 24, 2019 7:00 PM PDT

Promising Drug for Prostate Cancer

WRITTEN BY: Nouran Amin

Using high-throughput screening methods, cancer researchers from the UK have identified some promising drug candidates to test thousands of molecules. Specifically, they studied a protein called-methylacyl-CoA racemase (AMACR) as a potential target for therapeutics in prostate cancers. The experiments show that reducing the AMACR protein makes cancer cells less aggressive and allows their behavior to be like normal cells.

“The protein AMACR has been shown to be present in larger quantities in aggressive prostate cancer cells, and this research group have successfully developed a technique to find the protein and monitor its activity. Further to this, they have now found certain compounds that can target this protein's activity in the lab, and stop the cancer cells in their tracks,” says Simon Grieveson, Head of Research Funding at Prostate Cancer UK.

The study examined more than 20,000 drug-like molecules that inhibit the activity of AMACR using a method known as simple color-change technique. The technique allows for quick assessment of active compounds and identification of new types of drugs. Findings were published in the journal Bioorganic Chemistry.

Lead author Dr Matthew Lloyd said: "Although previously identified drugs are very effective in laboratory tests, in practice they are difficult to use in therapies because their properties do not allow easy distribution throughout the body. We started this study because we wanted to identify drugs which would be easier to use therapeutically. Although the particular compounds identified in this study did not kill prostate cancer cells very effectively, it is very promising that drug-like molecules were identified,” says lead author of the study, Dr. Matthew Lloyd rom the University of Bath.

Learn more about prostate cancer:

“The research is still in its infancy and is some way off from clinical investigation, however this is certainly promising and we look forward to seeing how this research progresses over the coming years,” says Grieveson.

Source: Science Daily

About the Author
Master's (MA/MS/Other)
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
NOV 29, 2022
Drug Discovery & Development
75g Kale Per Day Could Keep Bone Fractures Away
75g Kale Per Day Could Keep Bone Fractures Away
Vitamin K1- a nutrient found in leafy greens like kale, cabbage, and spinach- may help reduce bone fracture risk in elde ...
DEC 01, 2022
Drug Discovery & Development
The Impact of AI on Drug Discovery
The Impact of AI on Drug Discovery
Artificial Intelligence, also known as “AI”, has been the talk of the past year. AI performs and responds to ...
DEC 30, 2022
Health & Medicine
Individuals in Mid-Adulthood Sleep Less Than Younger and Older Adults
Individuals in Mid-Adulthood Sleep Less Than Younger and Older Adults
A study published in Nature Communications found that people sleep less on average in mid-adulthood than in early and la ...
JAN 05, 2023
Health & Medicine
A noninvasive sleep sensor that could prevent opioid overdose in recovering patients
A noninvasive sleep sensor that could prevent opioid overdose in recovering patients
Opioid Use Disorder (OUD) is a chronic condition of opioid use that results in significant distress, dependence, relapse ...
JAN 18, 2023
Neuroscience
Gene Linked to Alzheimer's Disease Predicts Who Benefits from Hormone Replacement Therapy
Gene Linked to Alzheimer's Disease Predicts Who Benefits from Hormone Replacement Therapy
Well established drug treatment might help some of the two-thirds of patients with Alzheimer's Disease.
JAN 29, 2023
Microbiology
Phase 2 Trial Shows Good Bacteria Can Stamp Out Bad Bacteria
Phase 2 Trial Shows Good Bacteria Can Stamp Out Bad Bacteria
We share the world, and our bodies with bacteria. Many of those microbes are harmless or even beneficial, while some can ...
Loading Comments...